Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR132 | Q9UNW8 | 8/20 | 0.51 |
| ▸ | ACACB | O00763 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MMP3 | P08254 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | EPOR | P19235 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1857509 | 0.89 | F2 (0.50) | ACACBRAB9AMMP2MMP3LTA4H | |
| SCHEMBL1856424 | 0.89 | GPR132 (0.54) | GPR132ACACBMMP13MAPK1MEN1 | |
| SCHEMBL1865673 | 0.89 | LTA4H (0.55) | RAB9AMMP2MMP3LTA4HEPOR | |
| SCHEMBL1857891 | 0.84 | MAOB (0.49) | GPR132MAPK1RAB9AADAMTS4MMP2 | |
| SCHEMBL1858392 | 0.81 | ALDH1A1 (0.57) | MEN1KMT2ARAB9AMMP2MMP3 | |
| SCHEMBL1859940 | 0.80 | GRIK1 (0.51) | KMT2AMMP2MMP3 | |
| SCHEMBL1856368 | 0.80 | PLAAT3 (0.50) | MMP13MMP2MMP3 | |
| SCHEMBL1856222 | 0.79 | OPRK1 (0.49) | — | |
| SCHEMBL1859995 | 0.78 | LTA4H (0.52) | MMP2MMP3LTA4H | |
| SCHEMBL1858600 | 0.78 | GRIK1 (0.54) | KMT2ARAB9AMMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2011-05-05 | — | — | US | disclosed |
| WO-2009080722-A2 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105544-A1 | CARBOXYLIC DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | AKR1C3, TPD52L2, HCCS | GPR132 361/4885ACACB 717/4885MMP13 3116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.